ETNB: 89bio Inc. Stocks News on June 2, 2025

ETNB

Insider Monkey

20 days ago

Why 89bio, Inc. (ETNB) Is Among the Best Low Priced Biotech Stocks to Buy Now

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB

GlobeNewswire

24 days ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio to Participate in Upcoming Investor Conferences

ETNB

GlobeNewswire

a month ago

89bio to Participate in Upcoming Investor Conferences

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

ETNB

GlobeNewswire

a month ago

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

ETNB

Investing.com

3 months ago

Citi says SMid biotechs alternative to large caps as it starts coverage

ETNB

MT Newswires

3 months ago

Citigroup Initiates 89bio Inc at Buy With $25 Price Target

ETNB

Zacks

3 months ago

Bears are Losing Control Over 89BIO (ETNB), Here's Why It's a 'Buy' Now

89bio to Participate in the Leerink Partners Global Healthcare Conference

ETNB

GlobeNewswire

3 months ago

89bio to Participate in the Leerink Partners Global Healthcare Conference

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

ETNB

GlobeNewswire

3 months ago

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

ETNB

Argus Research

3 months ago

Daily – Vickers Top Insider Picks for 02/21/2025

ETNB

Zacks

3 months ago

Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?

ETNB

Zacks

3 months ago

Should You Buy 89BIO (ETNB) After Golden Cross?

ETNB

Simply Wall St.

4 months ago

Institutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownership

ETNB

MT Newswires

4 months ago

89bio Closes $287.5 Million Public Offering

89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

ETNB

GlobeNewswire

4 months ago

89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

ETNB

GlobeNewswire

4 months ago

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

ETNB

Motley Fool

4 months ago

Why 89bio Stock Lagged the Market Today

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

ETNB

GlobeNewswire

4 months ago

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH Study

ETNB

Investor's Business Daily

4 months ago

Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH Study

ETNB

Argus Research

4 months ago

Daily – Vickers Top Buyers & Sellers for 01/24/2025

89bio Provides Business Update and Outlook for 2025

ETNB

GlobeNewswire

5 months ago

89bio Provides Business Update and Outlook for 2025

ETNB

Zacks

5 months ago

New Strong Sell Stocks for January 7th

ETNB

GlobeNewswire

5 months ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB

Insider Monkey

6 months ago

Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

ETNB

GlobeNewswire

6 months ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio to Participate in the 7th Annual Evercore HealthCONx Conference

ETNB

GlobeNewswire

6 months ago

89bio to Participate in the 7th Annual Evercore HealthCONx Conference

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

ETNB

GlobeNewswire

7 months ago

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

ETNB

GlobeNewswire

7 months ago

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

ETNB

GlobeNewswire

7 months ago

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

89bio Reports Third Quarter 2024 Financial Results and Corporate Updates

ETNB

GlobeNewswire

7 months ago

89bio Reports Third Quarter 2024 Financial Results and Corporate Updates

89bio to Participate in the UBS Global Healthcare Conference

ETNB

GlobeNewswire

7 months ago

89bio to Participate in the UBS Global Healthcare Conference

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH

ETNB

TipRanks

7 months ago

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH

ETNB

Investor's Business Daily

7 months ago

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH

Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings

ETNB

GuruFocus.com

7 months ago

Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings

State Street Corp's Strategic Acquisition in 89bio Inc

ETNB

GuruFocus.com

8 months ago

State Street Corp's Strategic Acquisition in 89bio Inc

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

ETNB

GlobeNewswire

8 months ago

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

ETNB

GlobeNewswire

8 months ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference

ETNB

GlobeNewswire

8 months ago

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference

ETNB

GlobeNewswire

8 months ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB

MT Newswires

9 months ago

89bio Appoints Teresa Perney as Chief Regulatory, Quality Officer

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

ETNB

GlobeNewswire

9 months ago

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

ETNB

GlobeNewswire

9 months ago

89bio to Participate in Upcoming Investor Conferences

ETNB

GlobeNewswire

10 months ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB

MT Newswires

10 months ago

89bio Names Francis Sarena Chief Operating Officer

89bio Appoints Francis Sarena as Chief Operating Officer

ETNB

GlobeNewswire

10 months ago

89bio Appoints Francis Sarena as Chief Operating Officer

89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

ETNB

GlobeNewswire

10 months ago

89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

ETNB

GlobeNewswire

a year ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB

GlobeNewswire

a year ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

ETNB

GlobeNewswire

a year ago

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

ETNB

GlobeNewswire

a year ago

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

ETNB

GlobeNewswire

a year ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB

GuruFocus.com

a year ago

89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical Trials

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

ETNB

GlobeNewswire

a year ago

89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

‘Jump on the Bandwagon,’ Says Bank of America About These 2 Stock Picks

ETNB

TipRanks

a year ago

‘Jump on the Bandwagon,’ Says Bank of America About These 2 Stock Picks

89bio to Participate in the BofA Securities 2024 Health Care Conference

ETNB

GlobeNewswire

a year ago

89bio to Participate in the BofA Securities 2024 Health Care Conference

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH

ETNB

GlobeNewswire

a year ago

89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

ETNB

GlobeNewswire

a year ago

89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors

ETNB

GlobeNewswire

a year ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio Inc CEO Rohan Palekar Sells 52,718 Shares

ETNB

GuruFocus.com

a year ago

89bio Inc CEO Rohan Palekar Sells 52,718 Shares

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

ETNB

GlobeNewswire

a year ago

89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That

ETNB

The Wall Street Journal

a year ago

Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That

ETNB

Insider Monkey

a year ago

13 Best Biotech Stocks To Buy Under $20

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

ETNB

GlobeNewswire

a year ago

89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ETNB

GlobeNewswire

a year ago

89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

89bio to Participate in the Leerink Partners Global Biopharma Conference

ETNB

GlobeNewswire

a year ago

89bio to Participate in the Leerink Partners Global Biopharma Conference

Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study

ETNB

Zacks

a year ago

Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study

ETNB

Zacks

a year ago

Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade

ETNB

Zacks

a year ago

89BIO (ETNB) Just Overtook the 200-Day Moving Average

Why Akero Rocketed — And Pulled Rival 89bio Higher — On Results In Liver Disease Treatment

ETNB

Investor's Business Daily

a year ago

Why Akero Rocketed — And Pulled Rival 89bio Higher — On Results In Liver Disease Treatment

Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs

ETNB

The Wall Street Journal

a year ago

Data Suggests Makers of Fatty Liver Treatments Won’t Be Displaced by Obesity Drugs

Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment

ETNB

Investor's Business Daily

a year ago

Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment

ETNB

GuruFocus.com

a year ago

89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ...

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

ETNB

GlobeNewswire

a year ago

89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

11 Best Small-Cap Growth Stocks to Invest In

ETNB

Insider Monkey

a year ago

11 Best Small-Cap Growth Stocks to Invest In

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

ETNB

GlobeNewswire

a year ago

89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

ETNB

GlobeNewswire

a year ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Purdy on how SF's experience with 'backs against wall' helps in adversity

ETNB

NFL Highlights

a year ago

Purdy on how SF's experience with 'backs against wall' helps in adversity

Ramaco Announces Hiring of Distinguished West Virginian as New General Counsel; First Quarter 2024 Class B Dividend Declared

ETNB

PR Newswire

a year ago

Ramaco Announces Hiring of Distinguished West Virginian as New General Counsel; First Quarter 2024 Class B Dividend Declared

ETNB

Associated Press Finance

a year ago

MaxLinear: Q4 Earnings Snapshot

The Cheesecake Factory to Webcast Fourth Quarter Fiscal 2023 Earnings Conference Call on February 21, 2024

ETNB

Business Wire

a year ago

The Cheesecake Factory to Webcast Fourth Quarter Fiscal 2023 Earnings Conference Call on February 21, 2024

MaxLinear, Inc. Announces Fourth Quarter and Fiscal Year 2023 Financial Results

ETNB

Business Wire

a year ago

MaxLinear, Inc. Announces Fourth Quarter and Fiscal Year 2023 Financial Results

Star Bulk Carriers Stock Sees RS Rating Improve To 71

ETNB

Investor's Business Daily

a year ago

Star Bulk Carriers Stock Sees RS Rating Improve To 71

Star Bulk Carriers (SBLK) Advances While Market Declines: Some Information for Investors

ETNB

Zacks

a year ago

Star Bulk Carriers (SBLK) Advances While Market Declines: Some Information for Investors

Apogee Enterprises Announces Strategic Actions to Reduce Costs and Strengthen the Company’s Position for Profitable Growth

ETNB

Business Wire

a year ago

Apogee Enterprises Announces Strategic Actions to Reduce Costs and Strengthen the Company’s Position for Profitable Growth

ETNB

Zacks

a year ago

The Zacks Analyst Blog Highlights Silicon Motion Technology, NVIDIA, Allegro MicroSystems and Ambarella

Kodiak Gas Services Announces Launch of $750 Million Senior Unsecured Notes Offering

ETNB

PR Newswire

a year ago

Kodiak Gas Services Announces Launch of $750 Million Senior Unsecured Notes Offering

ETNB

Associated Press Finance

a year ago

First Financial: Q4 Earnings Snapshot

First Financial Bancorp (FFBC) Reports Solid Loan Growth Amid Rising Funding Costs

ETNB

GuruFocus.com

a year ago

First Financial Bancorp (FFBC) Reports Solid Loan Growth Amid Rising Funding Costs

First Bancorp (FBNC) Reports Mixed Results Amidst GrandSouth Acquisition

ETNB

GuruFocus.com

a year ago

First Bancorp (FBNC) Reports Mixed Results Amidst GrandSouth Acquisition

First Busey (BUSE) Tops Q4 Earnings and Revenue Estimates

ETNB

Zacks

a year ago

First Busey (BUSE) Tops Q4 Earnings and Revenue Estimates

Procter & Gamble (PG) Beats Q2 Earnings Estimates, Ups EPS View

ETNB

Zacks

a year ago

Procter & Gamble (PG) Beats Q2 Earnings Estimates, Ups EPS View

Best Income Stocks to Buy for January 23rd

ETNB

Zacks

a year ago

Best Income Stocks to Buy for January 23rd

Best Value Stocks to Buy for January 23rd

ETNB

Zacks

a year ago

Best Value Stocks to Buy for January 23rd

ETNB

Investing.com

a year ago

Coinbase Global cut at JPMorgan amid Bitcoin ETF skepticism: 4 big analyst cuts

ETNB

Associated Press Finance

a year ago

Banner: Q4 Earnings Snapshot

Banner Corporation Reports Net Income of $42.6 Million, or $1.24 Per Diluted Share, for 4th Quarter 2023; Earns $183.6 Million in Net Income, or $5.33 Per Diluted Share, for the Full Year of 2023; Declares Quarterly Cash Dividend of $0.48 Per Share

ETNB

Business Wire

a year ago

Banner Corporation Reports Net Income of $42.6 Million, or $1.24 Per Diluted Share, for 4th Quarter 2023; Earns $183.6 Million in Net Income, or $5.33 Per Diluted Share, for the Full Year of 2023; Declares Quarterly Cash Dividend of $0.48 Per Share

Manufacturing Marvels: 3 Industrial Stocks Set for Success

ETNB

InvestorPlace

a year ago

Manufacturing Marvels: 3 Industrial Stocks Set for Success

Industry-First Center-Mounted Twin-Engine Barletta Pontoon Boat Honored with Innovation Award at Minneapolis Boat Show

ETNB

GlobeNewswire

a year ago

Industry-First Center-Mounted Twin-Engine Barletta Pontoon Boat Honored with Innovation Award at Minneapolis Boat Show

ETNB

Zacks

a year ago

89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average

ETNB

Business Wire

a year ago

Latest 89bio Inc. (ETNB) News on June 2, 2025

Share on Social Networks: